Multicenter, Multinational, Follow-Up Clinical Trial of the Performance of RESPINOR DXT to Identify Patients at Increased Risk of Weaning Failure
NCT ID: NCT05580185
Last Updated: 2023-12-18
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
145 participants
OBSERVATIONAL
2022-12-08
2023-07-30
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
All patients on mechanical ventilation in the ICU meeting the eligibility criteria shall undergo a daily screen for weaning readiness. If any of the components of the daily screen is not met, the patient will not undergo a SBT that day and continued to be screened daily. Patients passing daily screening criteria shall automatically receive an SBT.
The SBT shall last for 30-120 minutes and be performed on continuous positive airway pressure up to 5 cm H2O and pressure support up to 7 cm H2O. The SBT shall be terminated, and mechanical ventilation reinstituted at the original settings if the patient meets any of the SBT failure criteria.
A trial is considered successful, and physicians will be asked to approve extubation when the patient can breathe spontaneously for the whole trial.
As part of the clinical investigation, patients shall be continued to be screened daily until extubation, 21 days after enrollment, the performance of tracheostomy, death, or withdrawal of care. All patients shall be followed until hospital discharge or death.
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
During the SBT, the diaphragm excursion (DE) and respiratory rate shall be measured continuously using the investigative device, RESPINOR DXT, designed by the sponsor, RESPINOR (Oslo, Norway) for all patients.The continuous measurements shall be initiated 15 minutes prior to the SBT and last until 15 minutes post SBT. The investigator will be blinded to the DXT output. The DXT control unit will only display the signal needed to confirm good quality. During blinding mode, all quantifiable data are hidden from the screen; In the case DXT does not initiate blinding mode, the investigators shall enter this in the eCRF and report to the sponsor. In case of blinding failure, the patient will be excluded from the primary and secondary endpoint analysis (data marked as missing). Sensitivity analyses may, however, be conducted by including data pertaining to such unblinded patients. The patient can still be included in the descriptive secondary endpoints (including safety).
Additionally, information on VT and RR from the ventilator should be noted for the 2nd minute of the SBT.
The SBT will be interrupted and considered a failure in case of any of the SBT failure criteria:
* Respiratory rate \> 35 breaths/min
* Increased accessory muscle activity
* SpO2 persistently below 90% on FiO2 \< 0.4
* Heart rate persistently above 140 beats/min
* Systolic arterial blood pressure \< 90 mmHg or \> 180 mmHg
* Appearance of cyanosis or mottling
* Depressed mental status or agitation
A trial is considered successful, and physicians will be asked to approve extubation when the patient can breathe spontaneously for the whole trial. The patient may receive oxygen supplementation by nasal cannula or mask as needed.
The pathophysiology of weaning failure is often complex and multifactorial-respiratory, cardiac, and neurological problems can all cause weaning failure, especially in patients who have had prolonged stays in intensive care. It is therefore important to take a structured approach, identifying each factor and addressing it in turn. The physician will therefore log the failure criteria as well as the underlying reason for weaning failure.
Depressed mental status is one of the failure criteria of spontaneous breathing trials. A patient can have resolution of the acute phase of the disease for which the patient was intubated as well as adequate respiratory and cardiac function, but still have a depressed mental status leading to weaning failure. Depressed mental status will, in most cases, not affect the DE, and as such, DXT cannot predict patients who have weaning failure solely due to depressed mental status. Another cause for weaning failure unrelated to the DE is congestive heart failure. Consequently, if a patient has weaning failure solely due to depressed mental status or congestive heart failure, the patient will be excluded from the primary endpoint analysis.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Keywords
Explore important study keywords that can help with search, categorization, and topic discovery.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
COHORT
PROSPECTIVE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Weaning failure
Defined as the failure to pass a spontaneous breathing trial or the need for reintubation or death within 48 hours after extubation
RESPINOR DXT
Blinded, continuous diaphragmatic excursion measurements by DXT will be conducted during the patients' first SBT. The recording shall be initiated 15 minutes prior to the first SBT and will end 15 minutes post SBT.
Weaning success
Defined as a successful spontaneous breathing trial and is not reintubated or dies in the first 48 hours after extubation
RESPINOR DXT
Blinded, continuous diaphragmatic excursion measurements by DXT will be conducted during the patients' first SBT. The recording shall be initiated 15 minutes prior to the first SBT and will end 15 minutes post SBT.
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
RESPINOR DXT
Blinded, continuous diaphragmatic excursion measurements by DXT will be conducted during the patients' first SBT. The recording shall be initiated 15 minutes prior to the first SBT and will end 15 minutes post SBT.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
2. Have undergone invasive mechanical ventilation \>= 24 hours
3. Ready to wean according to criteria (from the sixth international consensus conference on intensive care medicine):
1. Adequate cough.
2. Absence of excessive tracheobronchial secretion.
3. Resolution of disease acute phase for which the patient was intubated.
4. Clinical stability, defined as stable cardiovascular status (i.e., fC \< 140 beats·min-1, systolic BP 90-160 mmHg, no or minimal vasopressors) and stable metabolic status.
5. Adequate oxygenation, defined as SaO2 \> 90% on \< FIO2 0.4 (or PaO2/FIO2 \> 150 mmHg) and PEEP \< 8 cmH2O.
6. Adequate pulmonary function, i.e., fR \< 35 breaths·min-1.
7. Adequate mentation, defined as no sedation or adequate mentation on sedation (or stable neurologic patient), i.e., patient awake, calm and responsive to simple orders (squeeze hand, knock the head, close the eyes), no agitation.
Exclusion Criteria
2. Central or spinal neurological injury involving central ventilatory control.
3. Presence of a neuromuscular disease involving respiratory muscles.
4. Use of muscle-paralyzing agents within 24h before the study, except if given for intubation.
5. Known paralysis of a hemidiaphragm or suspicion of paralysis of a hemidiaphragm, defined by the radiographic evidence of elevation of a dome \> 2.5 cm compared to the contralateral dome.
6. Tracheostomy.
7. Body mass index \>35 kg/m2.
8. Patient with therapeutic limitation, i.e., reduced expectancy to survive, defined by a Charlson Comorbidity Index \< 5%.
9. Pregnant woman or protected adult.
18 Years
99 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Centaur Clinical CRO
UNKNOWN
Link Medical Research AS
UNKNOWN
Respinor AS
INDUSTRY
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Alexandre Demoule, MD
Role: PRINCIPAL_INVESTIGATOR
Hôpital Universitaire Pitié Salpêtrière
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Hopital Saint-Antoine
Paris, Cedex 12, France
Hôpitaux Universitaires de Marseille - AP-HM
Marseille, Chem. Des Bourrely, France
Centre Hospitalier Universitaire de Montpellier
Montpellier, Select One..., France
CHU Angers
Angers, , France
Centre Hospitalier Saint Joseph Saint Luc
Lyon, , France
CH Saint Joseph Saint Luc
Lyon, , France
Hôpital Universitaire Pitié Salpêtrière
Paris, , France
Oslo University Hospital
Oslo, , Norway
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
DXT-CS-007
Identifier Type: -
Identifier Source: org_study_id